The press release says:
Macquarie University Hospital is participating in what will be the largest clinical trial to date assessing the effect of testosterone supplementation on reducing amyloid – a protein that develops in the part of the brain that affects memory and learning. Beta amyloid accumulation in the brain is a known cause of Alzheimer’s disease.
Participants will either receive testosterone supplementation alone or in combination with fish oil to determine if the amyloid load in the brain can be reduced, as well as whether the supplementation affects performance on tests of memory, cognition and function.
The ‘TotAL’ Trial will take 18 months from start to finish with 56 weeks of treatment and involve several hundred participants. The clinical part of the study is being led by MQ Health’s Professor David Gillatt and part of the Hospital’s urology team specialising in men’s health and male hormone therapies.
Macquarie University Hospital is participating in what will be the largest clinical trial to date assessing the effect of testosterone supplementation on reducing amyloid – a protein that develops in the part of the brain that affects memory and learning. Beta amyloid accumulation in the brain is a known cause of Alzheimer’s disease.
Participants will either receive testosterone supplementation alone or in combination with fish oil to determine if the amyloid load in the brain can be reduced, as well as whether the supplementation affects performance on tests of memory, cognition and function.
The ‘TotAL’ Trial will take 18 months from start to finish with 56 weeks of treatment and involve several hundred participants. The clinical part of the study is being led by MQ Health’s Professor David Gillatt and part of the Hospital’s urology team specialising in men’s health and male hormone therapies.
